You can now read 5 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

Red Sox Live

2

2

▲  3rd Inning 2 outs

Mass. Movers

ArQule slides again after study disappoints

Associated Press/File 2012

Continue reading below

Shares of ArQule Inc. of ­Woburn continued to slide after the company on Friday said a study showed the combined use of its lead drug candidate with two other cancer-fighting treatments did not meet survival targets for patients with a certain type of colorectal cancer. ArQule is engaged in the development of next-generation, small-molecule cancer therapeutics. Its products and research programs focus on key biological processes that are central to human cancers.

Loading comments...

Wake up with today's top stories.

Want each day's news headlines delivered fresh to your
inbox every morning? Just connect with us
in one of the following ways:
or
Please enter a valid email
BostonGlobe.com will never post anything without asking.
Privacy Policy
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com